⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
globenewswire.com
ABBV
AZN
BIIB
BMY
GSK
LLY
MRK
NVS
SNY
TEVA
UCB
Inveniam Hires Former Bloomberg and Moody's Leader to Meet Rising Institutional Demand for AI-Ready Data
prnewswire.com
IBM
MUFG
MS
GS
JPM
BAC
WFC
SCHW
AMTD
AXP
V
MA
PYPL
COF
SYK
BMY
PFE
MRK
JNJ
UNH
CVS
CI
AMGN
GILD
BIIB
REGN
AZN
NVS
TSM
NVDA
INTC
AMD
QCOM
AMAT
LRCX
MU
ADBE
CRM
GOOG
GOOGL
AMZN
MSFT
AAPL
META
NFLX
CMCSA
T
VZ
DIS
HD
MCD
SBUX
KO
PEP
CAT
BA
GE
XOM
CVX
HSBC
BCS
NYT
BKR
HAL
SLB
COP
EOG
APA
OXY
DVN
Merck Manuals: What Parents Need to Know About Kawasaki Disease
prnewswire.com
MRK
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
businesswire.com
MRK
TERN
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
globenewswire.com
RXRX
EXEL
MRK
BMY
GSK
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
globenewswire.com
MRK
TERN
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
businesswire.com
MRK
TERN
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
globenewswire.com
MRK
First Parkinson's Patients Treated in Landmark Phase 2 Trial of Dapansutrile - Expanding a Leading Oral NLRP3 Inhibitor into Neurological Diseases
prnewswire.com
MRK
eschbach Unveils Shiftconnector Activity Scheduler
prnewswire.com
MRK